中国科学院上海药物研究所前身是国立北平研究院药物研究所,创建于1932年,次年迁至上海,2003年搬迁至浦东张江高科技园区,是中国历史最悠久的综合性创新药物研究机构。
自建所以来,共研制开发新药100余种并投入生产,创制了一批在国内外具有一定影响的创新药物,如抗恶性疟疾首选药物蒿甲醚、重金属解毒药二巯丁二酸、抗肿瘤新药丁氧哌烷、抗阿尔茨海默症新药石杉碱甲、现代中药丹参多酚酸盐和抗菌新药盐酸安妥沙星等。2019年底,中国原创、国际首个靶向脑-肠轴的阿尔茨海默病(AD)治疗新药九期一(甘露特钠,代号:GV-971)获批上市,填补了这一领域17年无新药上市的空白。此外,一批抗恶性肿瘤、心脑血管疾病、自身免疫性疾病和抗感染性疾病的新药已进入临床研究。全所共获各类科研成果奖300余项,包括国家三大奖项27项,全国科学大会奖等国家级奖21项,省部级奖101项。
上海药物所瞄准国际生命科学发展的前沿领域以及药物研究的重要科学问题,开展创新药物基础和应用基础研究,发展药物研究新理论、新方法和新技术。重点围绕治疗恶性肿瘤、心脑血管系统疾病、神经精神系统疾病、代谢性疾病、自身免疫性疾病及感染性疾病等开展新药研发,并加强现代中药的研发。现设有五个国家级研究中心:新药研究国家重点实验室、国家新药筛选中心、中药标准化技术国家工程研究中心、国家化合物样品库、国家中药质量第三方检测(南方)中心,并建成了功能齐全、技术先进、综合集成、无缝衔接、运行高效、国际规范的综合性创新药物研发体系。
Shanghai Institute of Materia Medica, formerly the National Institute of Materia Medica, was founded in 1932 and moved to Shanghai in the following year. In 2003, it was relocated to Zhangjiang Hi-Tech Park in Pudong. It is the oldest comprehensive and innovative drug research institute in China.
Since its establishment, the institute has developed more than 100 new drugs and put them into production. A number of innovative drugs with certain influence both at home and abroad have been developed, such as artemether, the first choice anti-falciparum malaria drug, dimercaptobutyric acid, butoxidate, a new anti-tumor drug, perzine A, a new anti-Alzheimer's disease drug, salvianolate, a modern traditional Chinese medicine, and antifungal drugs such as antoxacin hydrochloride. At the end of 2019, China's original and the world's first new drug targeting brain-gut axis for the treatment of Alzheimer's disease (AD) phase 9 1 (Mannose sodium, code: GV-971) was approved to market, filling a 17-year gap in the field of new drugs on the market. In addition, a number of new drugs against malignant tumors, cardiovascular and cerebrovascular diseases, autoimmune diseases and anti-infectious diseases have entered clinical research. The Institute has won more than 300 awards for scientific research achievements, including 27 national awards, 21 national awards such as the National Science Congress, and 101 provincial and ministerial awards.
Aiming at the forefront of international life science development and important scientific issues in drug research, Shanghai Institute of Pharmaceutical Sciences carries out basic and applied basic research of innovative drugs, and develops new theories, new methods and new technologies in drug research. Focus on the treatment of malignant tumors, cardiovascular and cerebrovascular diseases, neuropsychiatric diseases, metabolic diseases, autoimmune diseases and infectious diseases to carry out new drug research and development, and strengthen the development of modern Chinese medicine. There are five national research centers: The State Key Laboratory for New Drug Research, the National Center for New Drug Screening, the National Engineering Research Center for Traditional Chinese Medicine Standardization Technology, the National Compound Sample Library, and the National Third-party Testing Center for Traditional Chinese Medicine Quality (South China), and has built a comprehensive innovative drug research and development system with complete functions, advanced technologies, comprehensive integration, seamless connection, efficient operation and international standards.